Blueprint Medicines Corpo... (BPMC)

NASDAQ: BPMC · Real-Time Price · USD

98.72

9.22 (10.30%)

At close: May 01, 2025, 12:09 PM

10.30% (1D)

Bid	69.92
Market Cap	6.37B
Revenue (ttm)	508.82M
Net Income (ttm)	-67.09M
EPS (ttm)	-1.07
PE Ratio (ttm)	-92.26
Forward PE	79.23
Analyst	Buy

Ask	116.19
Volume	769,894
Avg. Volume (20D)	1,072,429
Open	91.14
Previous Close	89.50
Day's Range	90.23 - 99.37
52-Week Range	73.04 - 121.90
Beta	0.75

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally avail...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 30, 2015

Employees 649

Stock Exchange NASDAQ

Ticker Symbol BPMC

Website https://www.blueprintmedicines.com

Full Company Profile

Analyst Forecast

According to 20 analyst ratings, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is $127.5, which is an increase of 29.16% from the latest price.

Stock Forecasts

Earnings Surprise

New

Blueprint Medicines has released their quartely earnings on May 1, 2025:

Revenue of $149.4M misses estimates by $7.49M, with 55.44% YoY growth.

EPS of 0.01 exceeds estimates by 0.45, with 100.76% YoY growth.

Next Earnings Release

Blueprint Medicines Corporation is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

Just now New

Blueprint Medicines shares are trading higher afte... Unlock content with Pro Subscription

2 months ago

-8.08%

Blueprint Medicines shares are trading lower after company reported worse-than-expected Q4 EPS results.

News

Just now · zacks.com

Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $1.32 per share a year ago.

1 week ago · zacks.com

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · seekingalpha.com

Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth

Blueprint Medicines' focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other promi...

2 months ago · zacks.com

BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline

Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the announcement.

2 months ago · seekingalpha.com

Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Cassie Saitow - Director, Investor Relations Kate Haviland - President...

2 months ago · zacks.com

Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.82 per share a year ago.

2 months ago · zacks.com

Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Should You Buy Blueprint Medicines (BPMC) After Golden Cross?

After reaching an important support level, Blueprint Medicines Corporation (BPMC) could be a good stock pick from a technical perspective. BPMC recently experienced a "golden cross" event, which saw i...